Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody‐associated Disease, Aquaporin‐4 Antibody‐Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis
Annals of Neurology · 2024-08 · 96 (2) · 276-288
DOI: 10.1002/ana.26951 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Neurology, online erschienen am 23.05.2024. Verfasst von Rosa Cortese und 47 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy. Hauptthemen laut MEDLINE: Aquaporin 4, Neuromyelitis Optica, Myelin-Oligodendrocyte Glycoprotein, Atrophy. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To evaluate: (1) the distribution of gray matter (GM) atrophy in myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD), aquaporin‐4 antibody‐positive neuromyelitis optica spectrum disorder (AQP4+NMOSD), and relapsing–remitting multiple sclerosis (RRMS); and (2) the relationship between GM volumes and white matter lesions in various brain regions within each disease.
Methods
A retrospective, multicenter analysis of magnetic resonance imaging data included patients with MOGAD/AQP4+NMOSD/RRMS in non‐acute disease stage. Voxel‐wise analyses and general linear models were used to evaluate the relevance of regional GM atrophy. For significant results ( p < 0.05), volumes of atrophic areas are reported.
Results
We studied 135 MOGAD patients, 135 AQP4+NMOSD, 175 RRMS, and 144 healthy controls (HC). Compared with HC, MOGAD showed lower GM volumes in the temporal lobes, deep GM, insula, and cingulate cortex (75.79 cm 3 ); AQP4+NMOSD in the occipital cortex (32.83 cm 3 ); and RRMS diffusely in the GM (260.61 cm 3 ). MOGAD showed more pronounced temporal cortex atrophy than RRMS (6.71 cm 3 ), whereas AQP4+NMOSD displayed greater occipital cortex atrophy than RRMS (19.82 cm 3 ). RRMS demonstrated more pronounced deep GM atrophy in comparison with MOGAD (27.90 cm 3 ) and AQP4+NMOSD (47.04 cm 3 ). In MOGAD, higher periventricular and cortical/juxtacortical lesions were linked to reduced temporal cortex, deep GM, and insula volumes. In RRMS, the diffuse GM atrophy was associated with lesions in all locations. AQP4+NMOSD showed no lesion/GM volume correlation.
Interpretation
GM atrophy is more widespread in RRMS compared with the other two conditions. MOGAD primarily affects the temporal cortex, whereas AQP4+NMOSD mainly involves the occipital cortex. In MOGAD and RRMS, lesion‐related tract degeneration is associated with atrophy, but this link is absent in AQP4+NMOSD. ANN NEUROL 2024;96:276–288
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
- Queen Square MS Center, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
- SIENA imaging SRL, Siena, Italy.
- Center for Medical Imaging Computing, Medical Physics, and Biomedical Engineering, UCL, London, UK.
- E-Health Center University Oberta de Catalunya, Barcelona, Spain.
- NMO Clinical Service at the Walton Centre, Liverpool, UK.
ORCID-Profile: Rosa Cortese, Alessia Bianchi, Lukas Haider, Silvia Messina, Friedemann Paul, Romain Marignier, Douglas Kazutoshi Sato, Massimo Filippi, Maria Assunta Rocca, Àlex Rovira, Jaume Sastre-Garriga, Yaou Liu, Claudio Gasperini, Matthias Grothe, Sara Llufriu, Carsten Lukas, Anne-Katrin Pröbstel, Jannis Müller, Bruno Stankoff
Zitieren
APA
Cortese, R., Battaglini, M., Prados, F., Gentile, G., Luchetti, L., Bianchi, A., Haider, L., Jacob, A., Palace, J., Messina, S., Paul, F., Marignier, R., Durand-Dubief, F., de Medeiros Rimkus, C., Apostolos Pereira, S. L., Sato, D. K., Filippi, M., Rocca, M. A., Cacciaguerra, L., …, & MAGNIMS Study Group (2024). Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody‐associated Disease, Aquaporin‐4 Antibody‐Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis. Annals of Neurology, 96(2), 276-288. https://doi.org/10.1002/ana.26951
Vancouver
Cortese R, Battaglini M, Prados F, Gentile G, Luchetti L, Bianchi A, et al. Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody‐associated Disease, Aquaporin‐4 Antibody‐Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis. Annals of Neurology. 2024;96(2):276-288. doi:10.1002/ana.26951
BibTeX
@article{Cortese2024,
author = {Cortese, Rosa and Battaglini, Marco and Prados, Ferran and Gentile, Giordano and Luchetti, Ludovico and Bianchi, Alessia and Haider, Lukas and Jacob, Anu and Palace, Jacqueline and Messina, Silvia and Paul, Friedemann and Marignier, Romain and Durand-Dubief, Françoise and de Medeiros Rimkus, Carolina and Apostolos Pereira, Samira Luisa and Sato, Douglas Kazutoshi and Filippi, Massimo and Rocca, Maria Assunta and Cacciaguerra, Laura and Rovira, Àlex and Sastre-Garriga, Jaume and Arrambide, Georgina and Liu, Yaou and Duan, Yunyun and Gasperini, Claudio and Tortorella, Carla and Ruggieri, Serena and Amato, Maria Pia and Ulivelli, Monica and Groppa, Sergiu and Grothe, Matthias and Llufriu, Sara and Sepulveda, Maria and Lukas, Carsten and Bellenberg, Barbara and Schneider, Ruth and Sowa, Piotr and Celius, Elisabeth G and Pröbstel, Anne-Katrin and Granziera, Cristina and Yaldizli, Özgür and Müller, Jannis and Stankoff, Bruno and Bodini, Benedetta and Barkhof, Frederik and Ciccarelli, Olga and De Stefano, Nicola and MAGNIMS Study Group, MAGNIMS Study Group},
title = {Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody‐associated Disease, Aquaporin‐4 Antibody‐Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis},
journal = {Annals of Neurology},
year = {2024},
volume = {96},
number = {2},
pages = {276--288},
doi = {10.1002/ana.26951}
}
EUVIMED